scholarly journals JAZF1–SUZ12 endometrial stromal sarcoma forming subserosal masses with extraordinary uptake of fluorodeoxyglucose on positron emission tomography: a case report

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Koto Fujiishi ◽  
Shigenori Nagata ◽  
Rieko Kano ◽  
Chiaki Kubo ◽  
Maasa Shirayanagi ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Endometrial Stromal Sarcoma ◽  
Emission Tomography ◽  
Low Grade ◽  
Neoplastic Cells ◽  
Pelvic Magnetic Resonance Imaging ◽  
Stromal Sarcoma ◽  
Positron Emission ◽  
Mesenchymal Neoplasm ◽  
The Right

Abstract Background Low-grade endometrial stromal sarcoma (ESS) is rare mesenchymal neoplasm, recently specified as harboring JAZF1–SUZ12 rearrangement. Typical JAZF1–SUZ12 ESS is slow growing, in which high uptake of fluorodeoxyglucose (FDG) on positron emission tomography (PET) and subserosal masses are quite unusual. Case presentation A 69-year-old Japanese woman complained of urinary incontinence. Pelvic magnetic resonance imaging showed uterine lesions composed of (1) a 9 × 8 × 7-cm mass protruding from the right-anterior wall, (2) a 4.5-cm mass attached to the right-posterior wall, and (3) a 6.5-cm intramural mass in the fundus. FDG-PET demonstrated maximum standardized uptake value of 13.28 confined to the two subserosal masses (1 & 2) in contrast to no uptake of the intramural mass (3). She was diagnosed with a high-grade uterine sarcoma concomitant with leiomyomas and underwent total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy. The removed uterus had three tumors—two in the right-anterior and right-posterior subserosa, respectively, and the remaining in the fundal myometrium. Microscopically, the three tumors shared morphologic features characterized by neoplastic cells similar to proliferative-phase endometrial stromal cells, in which neither round-cell component, pleomorphism, nor high mitotic activity was recognized. Nuclear cyclin D1 immunostaining was identified 50% of neoplastic cells in the two subserosal tumors (1 &2) whereas < 1% positive cells in the intramural component (3). Reverse transcriptase-polymerase chain reaction showed the same-sized electrophoretic bands indicating JAZF1–SUZ12 gene fusion shared by the three uterine tumors and a focal tumor extension into the extrauterine vein. The patient is alive without evidence of recurrence at 14 months after surgery. Conclusions Pathologists and clinicians should not exclude the possibility of JAZF1–SUZ12 ESS even when uterine subserosal masses demonstrate extraordinary FDG uptake on PET. Molecular analysis is helpful for diagnostic confirmation of JAZF1–SUZ12 ESS with a complex growth pattern.

The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review

2002 ◽  
Vol 97 ◽  
pp. 542-550 ◽  
Author(s):  
Marc Levivier ◽  
David Wikler ◽  
Nicolas Massager ◽  
Philippe David ◽  
Daniel Devriendt ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Brain Tumors ◽  
Treatment Planning ◽  
Target Volume ◽  
Emission Tomography ◽  
Low Grade ◽  
Content Type ◽  
Positron Emission ◽  
Pet Scanning ◽  
Fine Print

Object. The authors review their experience with the clinical development and routine use of positron emission tomography (PET) during stereotactic procedures, including the use of PET-guided gamma knife radiosurgery (GKS). Methods. Techniques have been developed for the routine use of stereotactic PET, and accumulated experience using PET-guided stereotactic procedures over the past 10 years includes more than 150 stereotactic biopsies, 43 neuronavigation procedures, and 34 cases treated with GKS. Positron emission tomography—guided GKS was performed in 24 patients with primary brain tumors (four pilocytic astrocytomas, five low-grade astrocytomas or oligodendrogliomas, seven anaplastic astrocytomas or ependymomas, five glioblastomas, and three neurocytomas), five patients with metastases (single or multiple lesions), and five patients with pituitary adenomas. Conclusions. Data obtained with PET scanning can be integrated with GKS treatment planning, enabling access to metabolic information with high spatial accuracy. Positron emission tomography data can be successfully combined with magnetic resonance imaging data to provide specific information for defining the target volume for the radiosurgical treatment in patients with recurrent brain tumors, such as glioma, metastasis, and pituitary adenoma. This approach is particularly useful for optimizing target selection for infiltrating or ill-defined brain lesions. The use of PET scanning contributed data in 31 cases (93%) and information that was specifically utilized to adapt the target volume in 25 cases (74%). It would seem that the integration of PET data into GKS treatment planning may represent an important step toward further developments in radiosurgery: this approach provides additional information that may open new perspectives for the optimization of the treatment of brain tumors.

11C-Methionine Positron Emission Tomography for Preoperative Evaluation of Suggestive Low-Grade Gliomas

2007 ◽  
Vol 68 (1) ◽  
pp. 19-23 ◽  
Author(s):  
H. Gumprecht ◽  
A. Grosu ◽  
M. Souvatsoglou ◽  
B. Dzewas ◽  
W. Weber ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Preoperative Evaluation ◽  
Emission Tomography ◽  
Low Grade ◽  
Low Grade Gliomas ◽  
Positron Emission

Whole body muscle activity during weightlifting exercise evaluated by positron emission tomography

2021 ◽  
Author(s):  
Rikuto Yoshimizu ◽  
Junsuke Nakase ◽  
Takafumi Mochizuki ◽  
Yasushi Takata ◽  
Kengo Shimozaki ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Muscle Activity ◽  
Erector Spinae ◽  
Triceps Surae ◽  
Emission Tomography ◽  
Whole Body ◽  
Computed Tomography Images ◽  
Positron Emission ◽  
The Right ◽  
Fdg Accumulation

Abstract BackgroundThis study investigated the whole-body skeletal muscle activity pattern of hang power clean (HPC), a major weight training exercise, using positron emission tomography (PET).MethodTwelve college weightlifting athletes performed three sets of HPC 20 times with a barbell set to 40 kg both before and after an intravenous injection of 37 MBq 18F-fluorodeoxyglucose (FDG). PET-computed tomography images were obtained 50 min after FDG injection. Regions of interest were defined within 71 muscles. The standardized uptake value was calculated to examine the FDG uptake of muscle tissue per unit volume, and FDG accumulation was compared to the control group. The Mann–Whitney U-test was used to evaluate the differences in the mean SUV between groups. The difference between SUVs of the right and left muscles was evaluated by a paired t-test. A P-value < 0.05 was considered statistically significant.ResultsFDG accumulation within the vastus lateralis, vastus intermedius, and vastus medialis was higher than that of the rectus femoris. FDG accumulation within the triceps surae muscle was significantly higher only in the soleus. In the trunk and hip muscles, FDG accumulation of only the erector spinae was significantly increased. In all skeletal muscles, there was no difference between SUVs of the right and left muscles.ConclusionsThe monoarticular muscles in the lower limbs were active in HPC. In contrast, deep muscles in the trunk and hip were not active during HPC. HPC is not suitable for core training and needs to be supplemented with other training.

Positron Emission Tomography in Diffuse Low-Grade Gliomas

2013 ◽  
pp. 235-248
Author(s):  
Karl-Josef Langen ◽  
Frank Willi Floeth ◽  
Michael Sabel ◽  
Norbert Galldiks
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Low Grade ◽  
Low Grade Gliomas ◽  
Positron Emission

Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL)

2001 ◽  
Vol 16 (4) ◽  
pp. 297-304 ◽  
Author(s):  
F. Najjar ◽  
R. Hustinx ◽  
G. Jerusalem ◽  
G. Fillet ◽  
P. Rigo
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Low Grade ◽  
Positron Emission ◽  
Hodgkin's Lymphomas

scholarly journals [11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas

ISRN Oncology ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Matteo Santoni ◽  
Cristina Nanni ◽  
Alessandro Bittoni ◽  
Gabriele Polonara ◽  
Alessandro Paccapelo ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Residual Disease ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
High Sensitivity ◽  
Emission Tomography ◽  
Low Grade ◽  
Postoperative Imaging ◽  
Positron Emission ◽  
Met Pet

We investigated the sensitivity and specificity of [11C]-methionine positron emission tomography ([11C]-MET PET) in the management of glioma patients. We retrospectively analysed data from 53 patients with primary gliomas (16 low grade astrocytomas, 15 anaplastic astrocytomas and 22 glioblastomas) and Karnofsky Performance Status (KPS) > 70. Patients underwent [11C]-MET PET scans (N=249) and parallel contrast-enhanced MRI (N=193) and/or CT (N=113) controls. In low grade glioma patients, MRI or CT findings associated with [11C]-MET PET additional data allowed discrimination residual disease from postsurgical changes in 96.22% of these cases. [11C]-MET PET early allowed detection of malignant progression from low grade to anaplastic astrocytoma with high sensitivity (91.56%) and specificity (95.18%). In anaplastic astrocytomas, we registered high sensitivity (93.97%) and specificity (95.18%) in the postoperative imaging and during the followup of these patients. In GBM patients, CT and/or MRI scans with additional [11C]-MET PET data registered a sensitivity of 96.92% in the postsurgical evaluation and in the tumour assessment during temozolomide therapy. A significant correlation was found between [11C]-MET mean uptake index and histologic grading (P<0.001). These findings support the notion that complementary information derived from [11C]-MET PET may be helpful in postoperative and successive tumor assessment of glioma patients.

2-(18F)-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Detects Clinical Relevant Adenomas of the Colon: A Prospective Study

2005 ◽  
Vol 23 (16) ◽  
pp. 3713-3717 ◽  
Author(s):  
Mariëtte C.A. van Kouwen ◽  
Fokko M. Nagengast ◽  
Jan B.M.J. Jansen ◽  
Wim J.G. Oyen ◽  
Joost P.H. Drenth
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Malignant Tumors ◽  
Case Series ◽  
Emission Tomography ◽  
Low Grade ◽  
Colonic Adenomas ◽  
Positron Emission ◽  
A Prospective Study ◽  
Fdg Accumulation

Purpose 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is a noninvasive imaging technique used clinically to detect malignant tumors. FDG-PET has been established as a tool for diagnosis of recurrent or metastatic colorectal carcinoma. Several case series suggest that FDG-PET also detects larger adenomas. The goal of this study was to investigate whether FDG-PET is able to detect colonic adenomas. Patients and Methods FDG-PET was performed in 100 consecutive patients in whom colonic adenomas were suspected on barium enema (n = 47) or sigmoidoscopy (n = 53). A positive scan was defined as focal large bowel FDG accumulation. FDG-PET was followed in all cases by colonoscopy, and removed adenomas were examined histopathologically. Results Colonoscopy confirmed the presence of adenomas in 68 of 100 patients. In 35 patients, there was focal FDG accumulation at site of the adenoma. The sensitivity of FDG-PET increased with adenoma size (21%, adenomas 1 to 5 mm; 47%, 6 to 10 mm; and 72%, > 11 mm). The sensitivity of FDG-PET also increased with the grade of dysplasia (33%, low grade; 76%, high grade; and 89%, carcinomas). The overall specificity was 84%. Conclusion FDG-PET detects colonic adenomas and the diagnostic test characteristics improve with size and grade of dysplasia of the adenoma.

Sign in / Sign up

Export Citation Format

Share Document